State of Alaska Department of Revenue Raises Stake in Qiagen (NYSE:QGEN)

State of Alaska Department of Revenue increased its stake in shares of Qiagen (NYSE:QGENGet Rating) by 186.7% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 85,618 shares of the company’s stock after purchasing an additional 55,753 shares during the period. State of Alaska Department of Revenue’s holdings in Qiagen were worth $4,041,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the stock. Dimensional Fund Advisors LP increased its stake in Qiagen by 31.2% in the 4th quarter. Dimensional Fund Advisors LP now owns 326,193 shares of the company’s stock worth $18,130,000 after acquiring an additional 77,604 shares during the last quarter. HighTower Advisors LLC increased its stake in Qiagen by 37.1% in the 4th quarter. HighTower Advisors LLC now owns 7,523 shares of the company’s stock worth $418,000 after acquiring an additional 2,036 shares during the last quarter. Rhumbline Advisers increased its stake in Qiagen by 2.5% in the 4th quarter. Rhumbline Advisers now owns 194,926 shares of the company’s stock worth $10,834,000 after acquiring an additional 4,734 shares during the last quarter. Public Sector Pension Investment Board increased its stake in Qiagen by 9.3% in the 4th quarter. Public Sector Pension Investment Board now owns 113,491 shares of the company’s stock worth $6,323,000 after acquiring an additional 9,633 shares during the last quarter. Finally, Gotham Asset Management LLC increased its position in shares of Qiagen by 117.3% during the 4th quarter. Gotham Asset Management LLC now owns 21,160 shares of the company’s stock valued at $1,176,000 after purchasing an additional 11,421 shares during the last quarter. Hedge funds and other institutional investors own 55.65% of the company’s stock.

Analyst Ratings Changes

Separately, StockNews.com lowered Qiagen from a “strong-buy” rating to a “buy” rating in a research report on Friday, July 29th. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $54.50.

Qiagen Price Performance

Shares of Qiagen stock opened at $42.38 on Thursday. The company has a current ratio of 2.23, a quick ratio of 1.89 and a debt-to-equity ratio of 0.45. The firm has a market capitalization of $9.62 billion, a PE ratio of 19.09, a price-to-earnings-growth ratio of 1.28 and a beta of 0.33. The business’s 50-day moving average price is $47.57 and its 200-day moving average price is $46.82. Qiagen has a 12 month low of $41.32 and a 12 month high of $58.00.

Qiagen (NYSE:QGENGet Rating) last issued its earnings results on Tuesday, July 26th. The company reported $0.51 earnings per share for the quarter, beating the consensus estimate of $0.45 by $0.06. The company had revenue of $515.51 million during the quarter, compared to analysts’ expectations of $498.09 million. Qiagen had a return on equity of 19.26% and a net margin of 22.75%. Sell-side analysts forecast that Qiagen will post 2.21 EPS for the current fiscal year.

Qiagen Profile

(Get Rating)

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.

Recommended Stories

Want to see what other hedge funds are holding QGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Qiagen (NYSE:QGENGet Rating).

Institutional Ownership by Quarter for Qiagen (NYSE:QGEN)

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.